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of the case mix of the hospital activity. As a consequence, it could be a useful model 
to increase the awareness of the economic impact and to allow a more informed 
management at hospital and regional level.
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Objectives: The aim of our study is to analyze the costs incurred by hospitalized 
patients in 2010, in the intensive care unit (ICU) of San Leonardo Hospital (Southern-
Italy). MethOds: A retrospective cost analysis was performed on patients with a 
length of stay longer than 24 hours. Direct medical costs were estimated (hospi-
talization, surgical procedures, devices). The costs of hospitalizations and surgical 
procedures were calculated based on the 24.0 version of the tariff system DRG 
(Diagnosis Related Group). The data on the costs of the devices were provided by 
the management of the hospital pharmacy. To evaluate the burden of the diagnostic 
groups two indicators were used: cost per surviving patient (total resources used / 
total survivors) and money loss per patient (total resources used for dead patients 
/ total patients) [Rossi et al. Intensive Care Med. 2006]. Results: A total of 201 
patients hospitalized in the ICU in 2010 were selected and analyzed depending on 
their diagnostic group. Hospitalized patients who had a hospital stay longer than 
or equal to 24 hours, were 95% of the sample. Most frequent diagnostic groups have 
been: edema (16.4%), left heart failure (13.9%) and COPD (9.0%). There is a wide vari-
ation between the average costs per patient probably due to the difference in the 
duration of hospitalization (from a minimum of € 2,777 in stroke, to a maximum 
of 7,227 euros in nephro-urological disease). Intracranial bleeding is the disease 
causing the highest costs per dead or survived patient. The nephro-urological and 
neurological diseases are characterized by the lowest costs, for dead and survived 
patients, indicating a better efficiency. cOnclusiOns: The results are a starting 
point for further investigations aimed at the exploitation of resources absorbed 
by ICU opposed to the need to provide patients with the best possible health care.
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Objectives: Medical nutrition (MN) targets patients with malnutrition or with 
specific disease such as Crohn’s disease (CD) to support their recovery. Efficacy of 
MN has been demonstrated in malnutrition, as well as in paediatric CD or gastro-
intestinal (GI) cancer surgery. However, its health economic evidence is less known. 
This article summarizes the findings of a systematic literature search on health 
economics evidence of MN in order to understand what the value for money of 
MN interventions is. MethOds: A systematic literature search was performed to 
identify publications related to health economics evidence of MN. The result of it 
was communicated elsewhere. For selected articles, the clinical background, basis 
of the analysis, health economic design and results were extracted and summa-
rized by relevant disease areas. Results: Among the 32 articles found, 11 covered 
malnutrition, 9 related to GI surgery, 6 studied cow milk allergies (CMA), whereas 
the remaining focused on various diseases. When targeting malnutrition, MN was 
accepted as being cost-effective and/or cost-savings from budget impact analyses. 
In GI surgery, when taking into account the full episode of care, oral and enteral 
nutrition was assessed as good value-for-money. In CMA, there was a significant 
health care budget impact of using MN to treat symptoms of this allergy. In the 
remaining indications, the use of enteral tube feeding was demonstrated as being 
cost-saving compared to parenteral nutrition. cOnclusiOns: Based on a system-
atic literature search, MN interventions showed value for money in different health 
care settings. Although few studies calculated an incremental cost-effectiveness 
ratio (ICER), those calculated were all below thresholds applied in medical settings. 
In addition, most of the times MN was more effective and cost saving, thus a domi-
nant option. However, more research is needed to strengthen economic modelling 
for medical nutrition interventions.
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Objectives: To assess the impact of recently published (2011) Guidelines for 
Pharmacoeconomic Evaluations for Serbia and ISPOR Guidelines (2013) on the 
methods and the conduct of budget impact analysis (BIA) during reimbursement 
submission. MethOds: We investigated how many reimbursement submissions 
were made with an accompanying BIA to the Health Insurance Fund in Serbia from 
2012 till June 2013. Results: There were 306 submissions in 2012 and 2013 and none 
of those had a thorough and complete BIA submitted. There were 65 new drugs 
(international non-proprietary names (INNs)) added to the Reimbursement list in 
2012 and 5 new drugs (INNs) in April 2013. Possible reason for a non-complete BIAs 
was that it is not an obligatory part of the submission dossier. It is recommended 
at this moment, but the plan is to make it an obligatory part. BIA simply quantifies 
the financial consequences of using health-care services, comparing reference with 
anticipated scenario. Currently there is no template for the BIA, just recommenda-
tions how to address time horizon, target population, costing, scenarios and dis-
counting. This could be one of the reasons why most of the submissions had almost 
complete pharmacoeconomics evaluation. cOnclusiOns: The availability of a 
template for BIA would increase transparency, the quality of submissions and pro-
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Contrast-induced nephropathy (CIN) is a clinically significant and costly com-
plication related to the use of iodine-based contrast media (CM). The hypothesis 
regarding the advantages of isoosmolar CM compared to low-osmolar CM was not 
confirmed in recent meta-analyses; still, there may be safety differences between 
individual CM. Objectives: To perform a pharmacoeconomic comparison of the 
CM ioversol and iohexol used for x-ray procedures in Russia. MethOds: We cal-
culated the costs for using ioversol and iohexol taking into account the risk of 
the occurrence of CIN and CIN-associated complications. Data for the model were 
extracted from published clinical trials and reviews. We performed an indirect com-
parison of both CM to calculate the relative risk (RR) of CIN (via the CM iodixanol as 
a mutual control). This RR value was used in the model to simulate the impact of 
potential safety differences between both CM on the costs. Direct medical costs were 
calculated based on the Russian health care system setting. Related costs for CM 
and for CIN-associated complications (e.g. cardiovascular complications, respiratory 
distress syndrome and hemodialysis for acute kidney injury) were also taken into 
account. Cost calculations were performed separately for patients with low, medium 
and high risk for CIN. One-way sensitivity analysis was performed. Results: RR of 
CIN was 0.26 (95% confidence interval 0.12-0.58) for ioversol vs iohexol in the indirect 
comparison. Direct medical costs were higher for iohexol than for ioversol due to 
the slightly higher rate of CIN, thus, CIN-associated complications: net benefits 
were 469.16; 752.88 and 3313.13 rubles (~11.03; 17.70; 77.91 Euros) per patient with 
low, medium and high risk of CIN correspondingly. Still, results were sensitive to 
the price of both CM. cOnclusiOns: In the Russian health care setting, the use 
of ioversol seems to be more cost efficient than iohexol due to slightly favorable 
renal safety.
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Objectives: Contrast-induced acute kidney injury (CI-AKI) is defined as a dete-
rioration in renal function after administration of radiologic iodinated contrast 
media (CM). Iodixanol, showed a lower CI-AKI incidence than low-osmolar contract 
media (LOCM). A cost-effectiveness analysis was performed comparing iodixanol 
and LOCM in intravenous (IV) setting in Italy. MethOds: A Markov model was 
developed. Patients moved across four health states, CI-AKI free, CI-AKI, myocar-
dial infarction and death. The simulation horizon was lifetime with one-month 
cycles. Costs and outcomes were discounted at 3.5% rate. CI-AKI incidence was 
considered from published literature across different definitions. Cost-effectiveness 
of iodixanol was assessed in terms of incremental cost per life year gained. Net 
monetary benefit (NMB) was also calculated. Both deterministic and probabilistic 
sensitivity analysis were performed. Results: Base-case results showed an aver-
age survival increase of 0.51 LYs and a saving of € 7.25 for iodixanol vs. LOCM. The 
cost-effectiveness of iodixanol was confirmed when other scenarios were explored, 
such as varying CI-AKI definition, sub-populations with specified risk factors, CM 
hospital bids prices and inclusion of adverse drug reactions of allergic nature. A NMB 
ranging between € 6,007.25 and € 30,007.25 was calculated. cOnclusiOns: base-
case results are showing that IV iodixanol is cost-effective compared to LOCM in 
the Italian clinical setting of hospital CT radiology practice. However, some caution 
is due, mainly linked to inherent limitations of the modelling technique and to the 
lack of agreement on CI-AKI incidence data in the clinical literature.
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Objectives: The Italian National Health Service (Servizio Sanitario Nazionale-SSN)is 
financed at hospital level by DRG (Diagnosis Related Group): the classification is 
defined at national level and the tariffs at regional level. Each region could define 
different tariffs for different types of hospital, choosing different criteria to identify 
them. The aim of this study is to analyze the incidence of the different types of 
costs for different surgical procedures and to evaluate the impact of the case mix 
on the total hospital costs. MethOds: We developed an excel model, the Win-Win, 
in order to analyze the incidence of different types of costs using the hospital per-
spective: length of stay, operating room time, personnel, materials. We identified 8 
surgical procedures, based on the International Classification of Disease 9-Clinical 
Modification, and for each one, we collected all the data from a survey based on 
different clinical practices in different types of hospitals. The model has been set 
up with the possibility to customize each type of data, consumptions and unit 
costs. Results: We calculated the average (AVG) and the confidence interval (IC) 
for the incidence of each type of cost among the different surgical procedures. For 
the length of stay we observed the highest average incidence (35,1%; IC95% 24,4-
39,9), followed by the cost of materials with an average of 34,9% (IC95% 30,1-43,1), 
the operating room cost (avg 20,6%; IC95% 18,8-22,8), and the personnel (avg 9,4%; 
IC95% 7,2-11,1). cOnclusiOns: Through the Win-Win Model it is possible to ana-
lyze the costs of each type of surgical procedure and evaluate the economic impact 
